TLDR: IGC Pharma’s Artificial Intelligence team has received a prestigious award from the National Institute on Aging (NIA) PREPARE Challenge for its ‘clean code’ development. This recognition highlights the company’s commitment to creating transparent, reusable, and well-structured AI code for an early Alzheimer’s detection platform, which leverages acoustic biomarkers and open data sources to identify cognitive decline.
POTOMAC, MD – September 9, 2025 – IGC Pharma, Inc. (NYSE American: IGC), a clinical-stage pharmaceutical company dedicated to Alzheimer’s disease therapies, announced today that its Artificial Intelligence (AI) team has been awarded for excellence in clean code development. This accolade was granted as part of the National Institute on Aging (NIA) PREPARE Challenge, underscoring IGC Pharma’s significant contribution to advancing scientific rigor and collaboration in Alzheimer’s research.
The award specifically recognizes IGC Pharma’s achievement in producing AI code that is well-structured, transparent, and highly organized, making it easily understandable and reusable by other researchers and developers. This commitment to ‘clean code’ not only propels the company’s efforts in Alzheimer’s detection but also fosters broader scientific community engagement by ensuring accessibility, interpretability, and reproducibility of its work.
Leveraging open data sources such as DementiaBank, a publicly available repository of speech and language samples from dementia patients, IGC Pharma’s AI team has developed a multilingual, interpretable AI model. This innovative platform is capable of detecting subtle acoustic biomarkers, which are linked to early cognitive decline. The modular and clean nature of their codebase ensures that these models can be readily scaled, tested, and adapted for use across diverse populations and contexts.
Ram Mukunda, CEO of IGC Pharma, commented on the achievement, stating, “Receiving recognition for clean code development reflects our deep commitment to scientific rigor, transparency, and collaboration. By making our AI work both powerful and reusable, we not only contribute to the broader Alzheimer’s research community but also strengthen our own pharmaceutical pipeline. These AI tools are instrumental for identifying and stratifying patients as part of our precision medicine approach, which in turn supports a multi-faceted commercialization strategy for our Alzheimer’s portfolio, including IGC-AD1, TGR-63, and IGC-M3. Together, our therapeutics and AI platforms create a differentiated path forward in addressing Alzheimer’s disease.”
Also Read:
- Agora Honored with Best Communications API Award at 2025 API World Conference for Conversational AI Engine
- Pistoia Alliance Launches Global Initiative for Responsible Agentic AI Adoption in Life Sciences
This recognition solidifies IGC Pharma’s position at the forefront of AI innovation in healthcare, particularly in the critical area of early Alzheimer’s detection and precision medicine.
